Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 5/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | CA7 | P43166 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2365401 | 0.97 | NR3C2 (0.81) | NR3C2ALDH1A1LMNAPOLBCA1 | |
| SCHEMBL2548305 | 0.94 | NR3C2 (0.75) | NR3C2ALDH1A1LMNAPOLBCA1 | |
| SCHEMBL2357173 | 0.92 | NR3C2 (1.00) | NR3C2LMNAPOLBTMPRSS4 | |
| SCHEMBL2545125 | 0.90 | NR3C2 (0.70) | NR3C2ALDH1A1CA1CA2CA9 | |
| SCHEMBL2365487 | 0.88 | NR3C2 (0.67) | NR3C2ALDH1A1CA1CA2CA9 | |
| SCHEMBL2365402 | 0.86 | NR3C2 (0.65) | NR3C2ALDH1A1LMNAPOLBCA1 | |
| SCHEMBL2548973 | 0.84 | NR3C2 (0.61) | NR3C2ALDH1A1CA1CA2CA9 | |
| SCHEMBL2359038 | 0.82 | NR3C2 (0.82) | NR3C2 | |
| SCHEMBL2357087 | 0.82 | NR3C2 (0.81) | NR3C2LMNAPOLBTMPRSS4 | |
| SCHEMBL2358751 | 0.81 | NR3C2 (0.80) | NR3C2ALDH1A1LMNAPOLBRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642640-B2 | 1-phenylpyrrole derivatives | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2349996-B1 | 1-PHENYLPYRROLE COMPOUNDS | EXELIXIS INC (US) | 2014-01-01 | — | — | EP | disclosed |
| US-20110263544-A1 | 1-Phenylpyrrole Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263544-A1 | 1-Phenylpyrrole Derivatives | REN, AGTR1, NR3C2 | NR3C2 3/4885ALDH1A1 252/4885LMNA 2828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.